Global Age-Related Macular Degeneration (VEGF) Market Study 2016 – Eylea Overtakes Lucentis – Research and Markets
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Age-Related Macular Degeneration (VEGF)" report to their offering. Eylea overtakes Lucentis in 2015 to become the highest selling anti-VEGF treatment for wet AMD, just four years after its first launch. This report addresses the following questions: - How do treatment practices vary in the US and EU between the three major VEGF inhibitors? - Why has Eylea been able to quickly position itself as a standard-of-care a
